Literature DB >> 1832460

Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient.

F Bevilacqua1, A Marcello, M Toni, M Zavattoni, M Cusini, R Zerboni, G Gerna, G Palù.   

Abstract

The biological characterization of a number of sequential herpes simplex virus type 2 (HSV-2) isolates obtained from an AIDS patient undergoing sequential courses of antiviral treatment due to an extended mucocutaneous genital lesion is reported. Resistance to acyclovir (ACV) and related compounds was linked to a thymidine kinase-deficient (TK-) phenotype. After ACV discontinuation and a course of treatment with foscarnet, a new isolate was recovered, characterized by loss of the ACV-resistant trait and production of a functional TK enzyme. Data presented stress the need for monitoring chemosensitivity of HSV isolates in AIDS patients while suggesting that for better control of the infection, these patients should benefit from alternative treatments with drugs aimed at different viral targets.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832460

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  5 in total

Review 1.  Strategies for antiviral screening targeting early steps of virus infection.

Authors:  Tao Peng
Journal:  Virol Sin       Date:  2010-07-28       Impact factor: 4.327

Review 2.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 3.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

4.  Houttuynia cordata targets the beginning stage of herpes simplex virus infection.

Authors:  Pei-Yun Hung; Bing-Ching Ho; Szu-Yuan Lee; Sui-Yuan Chang; Chuan-Liang Kao; Shoei-Sheng Lee; Chun-Nan Lee
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

Review 5.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.